Articles related to DISEASE-MODIFYING THERAPIES (DMTs)

An experimental cell therapy that couples a patient’s red blood cells with myelin protein fragments was well tolerated in a 10-patient Phase 1b study and was associated with increases in regulatory T-cells and reductions in neurofilament light chain, a biomarker linked to nerve injury.

Accumulating evidence suggests that initiating effective therapy earlier in Crohn’s disease may reduce bowel damage progression, hospitalizations, and surgery. Long-term follow-up from recent studies has strengthened interest in a therapeutic window during which disease modification may be achievable.

A network meta-analysis found that long-term vitamin D supplementation added to standard multiple sclerosis therapy was associated with reduced relapse risk and improved disability outcomes.

A network meta-analysis of 15 randomized trials found that no pharmacologic treatment outperformed placebo for MS-related fatigue severity, though amantadine and fampridine showed statistically significant and potentially clinically meaningful improvements in fatigue-related daily functioning.

A clinician review outlined how diagnostic confidence, staging, genetic risk, and imaging features inform patient selection for amyloid-targeting Alzheimer’s therapies.

Brain glucose levels regulated oligodendrocyte progenitor cell proliferation and maturation in mouse and cell models, with ketone bodies restoring myelin production when glucose use was disabled.